{"article_title":"Rapid Micro-induction of Buprenorphine\/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.","author":"Hamata, Basia , Griesdale, Donald , Hann, Jessica , Rezazadeh-Azar, Pouya","journal_title":"Journal of addiction medicine","issn":"1935-3227 ; Electronic","isbn":"","publication_date":"20201201","volume":"14","issue":"6","first_page":"514","page_count":"4","accession_number":"32649330","doi":"10.1097\/ADM.0000000000000675","publisher":"Wolters Kluwer Health, Inc","doctype":"Case Reports; Journal Article","subjects":"Medicine ","interest_area":["Emergency Medicine"],"abstract":"Buprenorphine\/naloxone has been shown to be an effective treatment of opioid use disorder. According to the Canadian National clinical practice guideline on the management of opioid use disorders, given the superior safety profile of buprenorphine\/naloxone and its potential for flexible take-home dosing in comparison to other opioid agonist medication it is strongly recommended to initiate opioid agonist treatment with buprenorphine\/naloxone as the preferred first-line treatment when possible. Due to its pharmacological properties induction can be challenging, requiring the cessation of all opioids for a certain amount of time to avoid the risk of precipitated withdrawal symptoms. For this reason, buprenorphine\/naloxone is not initiated for the treatment of opioid use disorder in critically ill patients where continuous infusion of opioids are required for maintenance of sedation resulting in a missed opportunity for first line treatment of that patient's opioid use disorder.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=32649330&authtype=shib&custid=ns346513"}
Buprenorphine/naloxone has been shown to be an effective treatment of opioid use disorder. According to the Canadian National clinical practice guideline on the management of opioid use disorders, given the superior safety profile of buprenorphine/naloxone and its potential for flexible take-home dosing in comparison to other opioid agonist medication it is strongly recommended to initiate opioid agonist treatment with buprenorphine/naloxone as the preferred first-line treatment when possible. Due to its pharmacological properties induction can be challenging, requiring the cessation of all opioids for a certain amount of time to avoid the risk of precipitated withdrawal symptoms. For this reason, buprenorphine/naloxone is not initiated for the treatment of opioid use disorder in critically ill patients where continuous infusion of opioids are required for maintenance of sedation resulting in a missed opportunity for first line treatment of that patient's opioid use disorder.
